CLINICAL CHARACTERISTICS OF OUR PATIENTS WHO DIED DUE TO COVID-19

Yıl 2023, Cilt: 24 Sayı: 2, 179 - 183, 05.04.2023

İmren Taşkıran , Yosun Şan , Melda Turken , Gürsel Ersan , Şükran Köse

https://doi.org/10.18229/kocatepetip.1075743

Öz

OBJECTIVE: The coronavirus disease 2019 (COVID-19), which has just been encountered by the whole world and has rapidly affected the world, started to spread quickly in our country, with the first case seen in Turkey as of March 11, 2020. In our study, it was aimed to examine the demographic data, clinical and laboratory evaluation, discharge and mortality rates of the patients who died from the COVID-19 patients we followed up in our hospital for a year.
MATERIAL AND METHODS: The patient files of 3650 cases followed up with the diagnosis of COVID-19 in our hospital between 11.03.2020 - 31.03.2021 were examined. Mortal cases were evaluated retrospectively.
RESULTS: During the pandemic in this period, our hospital mortality rate is 11.3%. 255 (62,8) were male patients and the median age was 72 (18-106). The most frequent accompanying chronic diseases were hypertension in 141 (34,7) patients, followed by chronic kidney disease in 113 (27,8) patients. It was observed that the most common symptom at the time of admission was dyspnea (57,6). The median d-dimer value in the examinations of the patients was 1955 ng/mL (40-25810), and the median ferritin value was 450 ng/mL (9-10157). Thorax computed tomography images of 237 (94) patients were reported to be compatible with covid-19 pneumonia.
CONCLUSIONS: In our study, our cases of mortality due to COVID-19 disease with a pandemic course were evaluated. It has been observed that male, older age, patients with hypertension and chronic kidney disease have a high rate among patients who have died from COVID-19.

Anahtar Kelimeler

COVID-19, Comorbidity, Mortality, SARS-CoV-2

COVİD 19 NEDENİYLE ÖLEN HASTALARIMIZIN KLİNİK ÖZELLİKLERİ

Öz

AMAÇ: Tüm dünyanın yeni karşılaştığı ve hızla dünyayı etkisi altına alan koronavirüs hastalığı 2019 (COVID-19), 11 Mart 2020‘den itibaren Türkiye’de ilk vakanın görülmesi ile birlikte ülkemizde de hızla yayılmaya başladı ve beraberinde ölümleri de getirdi. Çalışmamızda bir yıllık süre içinde hastanemizde yatarak takip ettiğimiz ve mortal seyreden COVID-19 tanılı olguların demografik verileri, klinik ve laboratuvar değerlendirilmesi ve mortalite oranlarının irdelenmesi amaçlanmıştır.
GEREÇ VE YÖNTEM: 11.03.2020 - 31.03.2021 tarihleri arasında hastanemizde COVID-19 tanısı ile takip edilen 3650 olgunun hasta dosyaları incelendi. Mortal seyreden olgular değerlendirildi.
BULGULAR: Pandemi sürecinde bu dönemdeki hastanemizde COVID-19 tanısı ile servis ve yoğun bakımda takip edilen toplam 3650 hastada mortalite oranı % 11,3’tür. Çalışmaya dahil edilen 406 hastanın 255’i (%62,8) erkek ve ortanca yaş 72 (18-106) olarak saptandı. En fazla eşlik eden kronik hastalıklar 141 (%34,7) hastada hipertansiyon, ikinci sırada ise 113 (%27,8) hastada kronik böbrek hastalığıydı. Başvuru anında en sık görülen semptomun dispne (%57,6) olduğu gözlendi. Hastaların başvuru tetkiklerindeki ortanca d-dimer değeri 1955 ng/mL (40-25810) , ortanca ferritin değeri de 450 ng/mL (9-10157) olarak hesaplandı. Hastalarımızın 237 (%94) ‘sinin toraks bilgisayarlı tomografi görüntüleri COVID-19 pnömonisi ile uyumlu raporlandı.
SONUÇ: Çalışmamızda pandemik seyir gösteren COVID-19 hastalığı nedeniyle mortal seyreden olgularımız irdelenmiş; erkek cinsiyet, ileri yaş, hipertansiyon ve kronik böbrek hastalığı olan hastaların, COVID-19’dan ölen hastaların içinde yüksek oranda bulundukları gözlemlenmiştir.

Anahtar Kelimeler

COVID-19, Komorbidite, Mortalite, SARS-Cov-2

Kaynakça

• 1. Chan JWM, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003;58:686–89.
• 2. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199-1207.
• 3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
• 4. Parohan M, Yaghoubi S, Seraji A, et al. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;23(5):1416-1424.
• 5. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:1091.
• 6. Albitar O, Ballouze R, Ooi JP, Sheikh Ghadzi SM. Risk factors for mortality among COVID-19 patients. Diabetes Res Clin Pract. 2020;166:108293.
• 7. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. 2020;8:20.
• 8. Lancet The. The gendered dimensions of COVID-19. Lancet 2020;395:1168.
• 9. Zhang J jin, Dong X, Cao Y yuan, Yuan Y dong, Yang Y bin, Yan Y qin, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy Eur J Allergy Clin Immunol. 2020;75(7):1730-41.
• 10. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-38.
• 11. Hussain A, Bhowmik B, Cristina do Vale Moreira N. COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142.
• 12. Aggarwal G, Cheruiyot I, Aggarwal S, Wong J, Lippi G, Lavie CJ, et al. (COVID-19) severity: a meta-analysis. Curr Probl Cardio. 2020;45(8):100617.
• 13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;28:395(10229):1054-1062.
• 14. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21(1):855.